Drug testing for teratogenicity: its implications, limitations and application to man.
D000014:Abnormalities, Drug-Induced / Q000145:classification / Q000209:etiology*; D000028:Abortion, Induced; D000818:Animals; D000830:Animals, Laboratory; D003142:Communication; D003201:Computers; D004353:Drug Evaluation, Preclinical; D004622:Embryo, Mammalian / Q000378:metabolism; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007928:Lethal Dose 50; D008722:Methods; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010600:Pharmacology / Q000193:education; D011247:Pregnancy; D011323:Primates; D011868:Radioisotopes; D012109:Research Support as Topic; D013045:Species Specificity; D013723:Teratogens; D013792:Thalidomide / Q000494:pharmacology; D014481:United States; D014486:United States Food and Drug Administration
D004364:Pharmaceutical Preparations; D011868:Radioisotopes; D013723:Teratogens; D013792:Thalidomide